Endo International Plc has agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic, the company announced last month.
The settlement came just days before the case was set to go to trial to decide damages, in which plaintiffs were expected to seek $2.4 billion. A judge had previously ruled Endo liable as a penalty for failing to hand over evidence.
Endo shares had jumped about 25% after local government officials revealed that the drugmaker had made a settlement offer.
The lawsuit, which was filed in 2017, is being pursued by several local governments and a “Baby Doe” allegedly born with neonatal abstinence syndrome, which is caused by withdrawal after in-utero opioid exposure.
The plaintiffs alleged that Endo downplayed the risks of its painkiller Opana ER, which was pulled from the market in 2017 due to concerns about abuse. OxyContin maker Purdue Pharma and generic opioid maker Mallinckrodt Plc were also named as defendants in the case, but subsequently filed for bankruptcy, leaving Endo as the only active defendant.
Was this article valuable?
Here are more articles you may enjoy.
London Broker Howden Plots Giant Capital Raise on IPO Path 
Majority of Small Business Are Underinsured as Other Expenses Prioritized 
Insurer Interest in AI Exclusions Growing as Risk Becomes Omnipresent 
Why El Ni帽o’s Promise of Quieter Hurricane Season May Not Be Good News for Insurers From This Issue
